BioCentury | Nov 10, 2014
Company News

Marinomed, Nicox deal

...Nicox acquired Marinomed's Carragelose antiviral eye drop program for EUR2.7 million ($3.3 million) in newly issued...
...eye drop program for EUR2.7 million ($3.3 million) in newly issued Nicox shares up front. Marinomed...
...derived from red algae. Marinomed markets Carragelose as an OTC product for respiratory viral infections. Marinomed...
BioCentury | Nov 7, 2011
Company News

Marinomed management update

Marinomed Biotechnologie GmbH , Vienna, Austria Business: Infectious, Inflammation Hired: Angelika Bodenteich as head of development, formerly CMO of onepharm Research & Development GmbH WIR Staff...
BioCentury | Jun 7, 2010
Clinical News

Marinomed preclinical data

...an anti-inflammatory compound derived from Aesculus hippocastanum seed extracts. Data were published in BMC Immunology. Marinomed...
BioCentury | Sep 28, 2009
Company News

Bioalvo, Marinomed deal

...screen Bioalvo's PharmaBUG marine extract library to identify drug candidates for immunology and infectious disease. Marinomed...
...resulting products for the indications. Financial terms were not disclosed. Bioalvo S.A. , Lisbon, Portugal Marinomed...
BioCentury | Jun 15, 2009
Company News

Medimetriks Pharmaceuticals Inc., PharmaMar deal

...peroxide for acne vulgaris. In March, PharmaMar out-licensed two different analogs of Kahalalide F to Marinomed...
BioCentury | Mar 9, 2009
Company News

Marinomed, PharmaMar deal

...Spain Business: Autoimmune, Infectious The partners will identify and synthesize analogs of PharmaMar's Kahalalide F. Marinomed...
...from Elysia rufescens for uses outside of oncology and neurology, where PharmaMar will retain rights. Marinomed...
...development and commercialization. PharmaMar is eligible for royalties and a portion of income received by Marinomed...
Items per page:
1 - 6 of 6
BioCentury | Nov 10, 2014
Company News

Marinomed, Nicox deal

...Nicox acquired Marinomed's Carragelose antiviral eye drop program for EUR2.7 million ($3.3 million) in newly issued...
...eye drop program for EUR2.7 million ($3.3 million) in newly issued Nicox shares up front. Marinomed...
...derived from red algae. Marinomed markets Carragelose as an OTC product for respiratory viral infections. Marinomed...
BioCentury | Nov 7, 2011
Company News

Marinomed management update

Marinomed Biotechnologie GmbH , Vienna, Austria Business: Infectious, Inflammation Hired: Angelika Bodenteich as head of development, formerly CMO of onepharm Research & Development GmbH WIR Staff...
BioCentury | Jun 7, 2010
Clinical News

Marinomed preclinical data

...an anti-inflammatory compound derived from Aesculus hippocastanum seed extracts. Data were published in BMC Immunology. Marinomed...
BioCentury | Sep 28, 2009
Company News

Bioalvo, Marinomed deal

...screen Bioalvo's PharmaBUG marine extract library to identify drug candidates for immunology and infectious disease. Marinomed...
...resulting products for the indications. Financial terms were not disclosed. Bioalvo S.A. , Lisbon, Portugal Marinomed...
BioCentury | Jun 15, 2009
Company News

Medimetriks Pharmaceuticals Inc., PharmaMar deal

...peroxide for acne vulgaris. In March, PharmaMar out-licensed two different analogs of Kahalalide F to Marinomed...
BioCentury | Mar 9, 2009
Company News

Marinomed, PharmaMar deal

...Spain Business: Autoimmune, Infectious The partners will identify and synthesize analogs of PharmaMar's Kahalalide F. Marinomed...
...from Elysia rufescens for uses outside of oncology and neurology, where PharmaMar will retain rights. Marinomed...
...development and commercialization. PharmaMar is eligible for royalties and a portion of income received by Marinomed...
Items per page:
1 - 6 of 6